Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Patients in CheckMate 067 Demonstrate Durable Complete Responses

Georgina V. Long, BSc, PhD, MBBS, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses the response rates in the CheckMate 067 trial (NCT01844505), which evaluated the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with advanced […]

Inherited genetic variations can alter progression of melanoma, indicates study

Sometimes cancer stays put, but often it metastasizes, spreading to new locations in the body. It has long been suspected that genetic mutations arising inside tumor cells drive this potentially devastating turn of events.

Melanoma Articles for Feb-April 2020

Please click on the link to see a list of melanoma journal articles that came across the MRV desk recently.

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

Given that objective responses in 30% to 50% of patients suffering from metastatic melanoma is mediated by adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), as per multiple, small phase 2 trials, so, researchers assessed long-term clinical outcomes, intent-to-treat analysis, predictors of response as well as toxicity profile in a large patient cohort.